Medical Oncology

Inclusion Criteria

- Male or female subjects aged >/= 18 years.
 - Study population:
 -- For the dose-escalation cohorts:  Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors), refractory to any standard therapy, have no standard therapy available
 -- For the expansion cohort:  Subjects with advanced, histologically or cytologically confirmed triple-negative breast cancer (TNBC), refractory to any standard therapy, have no standard therapy available, or subjects actively refused any standard treatment and / or if, in the judgment of the investigator, experimental treatment is clinically acceptable.
 - Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
 - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
 - Life expectancy of at least 12 weeks.
 - Adequate bone marrow, liver, and renal functions.

Exclusion Criteria

- Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.
 - Evidence of peripheral neuropathy of Grade >2.
 - History of cardiac disease:  congestive heart failure New York Heart Association (NYHA) class >II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months before study entry), myocardial infarction within the past 3 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted).
 - Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg, despite optimal medical management.
 - Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C.
 - History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.